Could the key to managing your health be hidden in your genes?
As science reveals more and more about genetics, Fairview is exploring the role your genes can play in determining your best treatment options for high blood pressure.
Often called the “silent killer,” high blood pressure impacts 1 in 3 American adults, costs the nation $46 billion annually and kills 1,000 Americans every day.
To radically improve health outcomes for patients managing high blood pressure, Fairview is embarking on a year-long, 800-person prospective research study involving gene-specific treatment protocols.
“We believe we can dramatically cut the time, cost and side effects involved in managing high blood pressure through the use of gene-specific treatment protocols,” said Dang Tran, MD, vice president of medical practice, Fairview Medical Group, and principal investigator for the study.
Qualified patients may have the opportunity to enroll in the randomized controlled clinical research trial, which is believed to be the largest prospective study of personalized medicine for the treatment of high blood pressure ever conducted.
Eight Fairview clinics will participate in the study: Andover, Brooklyn Park, Burnsville, Columbia Heights, Fridley, New Brighton, Bloomington/Oxboro and Wyoming.
To conduct the study, Fairview has entered into a clinical research agreement with Geneticure, a Minnesota-based pharmacogenomics testing company. Early research indicates Geneticure’s patented genetic test can help clinicians personalize hypertension treatment resulting in faster, better care.
“The implications for the nation’s health are staggering,” says Bob Beacher, RPh, president, Shared Clinical Services, Fairview. “Uncontrolled hypertension contributes to strokes, coronary heart disease and cardiovascular disease. The findings from this research could transform the health of an entire population.”